Ayahuasca

# Research Output: Ayahuasca

---

## Botanical Identity

**Preparation note:** Ayahuasca is a botanical *preparation*, not a single plant. It is a psychoactive decoction prepared from at minimum two plant species. The primary vine is *Banisteriopsis caapi*; the primary admixture plant providing DMT is *Psychotria viridis*. The brief's seed data correctly classifies ayahuasca as a preparation, not a plant species.

### Vine: *Banisteriopsis caapi* (Spruce ex Griseb.) C.V.Morton

- **Family:** Malpighiaceae
- **Accepted binomial:** *Banisteriopsis caapi* (Spruce ex Griseb.) C.V.Morton [Ref 21]
- **First publication:** J. Washington Acad. Sci. 21: 486 (1931), as formalized by C.V.Morton. The species was originally described by Richard Spruce during his 1849–1864 Amazon expedition, published as *Banisteria caapi* Spruce ex Griseb.
- **Synonyms (POWO-verified):** *Banisteria caapi* Spruce ex Griseb. (homotypic); *Banisteria inebrians* (C.V.Morton) J.F.Macbr.; *Banisteria quitensis* Nied.; *Banisteriopsis inebrians* C.V.Morton; *Banisteriopsis quitensis* (Nied.) C.V.Morton [Ref 21]
- **Native range:** South Tropical America — Argentina (Northwest), Bolivia, Brazil (North and West-Central), Colombia, Ecuador, Peru, Venezuela [Ref 21]
- **Habit:** Climbing liana/vine; grows primarily in wet tropical biome; can reach up to 30 m in length; bark chocolate-brown and smooth; opposite oval leaves 8–18 cm long, 3.5–8 cm wide; white or pale pink flowers 12–14 mm diameter [web-retrieved: Banisteriopsis caapi description]
- **Cultivation status:** Both wild-harvested and cultivated; actively cultivated by indigenous communities and for ceremonial use; also wild-collected throughout native range
- **Misidentification risk:** Multiple *Banisteriopsis* species exist, some without significant alkaloid content. However, the vine's morphological distinctiveness and established cultivar recognition among traditional practitioners reduces practical risk at the source. Commercial preparations from unverified suppliers carry adulteration and misidentification risk.

### Primary Admixture Plant: *Psychotria viridis* Ruiz & Pav.

- **Family:** Rubiaceae
- **Common names:** Chacruna (Peru/Brazil), sami ruca (indigenous)
- **Habit:** Perennial shrub native to tropical Amazonian rainforests
- **DMT content:** Leaves contain 0.1–0.61% DMT dry weight; analytical study of 37 Brazilian samples found range 0.00–17.65 mg/g dried leaf; average approximately 10 mg/g [Ref 43]. Daily variation documented: highest DMT concentrations at dawn and pre-dusk collections.
- **Note:** POWO taxonomy for *P. viridis* not retrieved in this research run. **FLAGGED for human review.**

### Alternative Admixture Plants (documented)

- *Diplopterys cabrerana* (Malpighiaceae) — Chagropanga/Chaliponga; also contains DMT; used in Western Amazon regions (Colombia, Ecuador)
- *Psychotria carthagenensis* Jacq. — Amyruca; used less commonly [Ref 10]
- McKenna et al. 1984 [Ref 10]: three admixture plants were screened; all provide DMT but concentrations and brew potency differ. No published PK studies specifically comparing P. viridis vs D. cabrerana substitution in human subjects.

### Discrepancies with Brief's Seed Data

- Brief lists "no seed data" for family, genus/species, native range, and cultivation status. All have now been verified above.
- Brief type "preparation" is confirmed correct — ayahuasca is not a single plant but a multi-plant decoction.

---

## Alkaloid / Cannabinoid Profile

### Beta-Carbolines in *Banisteriopsis caapi* Vine

Quantitative analysis of dried vine material [Refs 10, 31, 35, 42]:
- **Harmine** (PubChem CID 5280953; C₁₃H₁₂N₂O; MW 212.25): Dominant alkaloid; dry stem content 0.31–8.43%; mean ~4.79 mg/g. Reversible, competitive MAO-A inhibitor. Also inhibits DYRK1A, dopamine transporter, imidazoline receptors [Ref 6].
- **Harmaline** (PubChem CID 3564; C₁₃H₁₄N₂O; MW 214.26): 0.03–0.83%; mean ~0.451 mg/g. More potent CNS-active MAO-A inhibitor than harmine; most toxic beta-carboline in preclinical models [Ref 3].
- **Tetrahydroharmine (THH)** (PubChem CID 442118; C₁₃H₁₆N₂O; MW 216.28): 0.05–2.94%; mean ~2.18 mg/g. Weak serotonin reuptake inhibitor (SERT); minor MAO-A inhibition. Second most abundant alkaloid. May form additionally from harmine and harmaline during the boiling process of preparation [Ref 31].

Considerable inter-sample variability documented across cultivars, geographic sources, and batches. Callaway (2005) [Ref 31] analyzed 29 B. caapi decoctions and found wide variation in alkaloid profiles within and between sources.

### Primary Psychedelic Constituent in Admixture Plants

- **N,N-Dimethyltryptamine (DMT)** (PubChem CID 6089; C₁₂H₁₆N₂; MW 188.27; IUPAC: 2-(1H-indol-3-yl)-N,N-dimethylethanamine): Derived from *P. viridis* leaves; 0.1–0.61% dry weight; trace MMT also present [Refs 10, 43].

### Prepared Brew Composition

Analytical studies of real ayahuasca brews [Refs 18, 31]:
- DMT concentration in ceremonial brews: 0.05–14.2 mg/mL (wide range); research analytical studies show typical ranges of 0.24–0.36 mg/mL in Brazilian religious brews (24–36 mg per 100 mL dose); forensic analysis of seized preparations shows 45.7–230.5 mg/L
- Typical ceremonial serving (~100 mL): approximately 25–100 mg DMT
- No standardized composition exists; alkaloid profile is preparation-dependent

### Preparation Method and Constituent Ratios

Traditional preparation involves prolonged aqueous decoction (boiling) of *B. caapi* stem/bark together with *P. viridis* leaves (or alternative admixture plants) in water for several hours; the liquid is then strained and the process repeated; the decoctions are combined and reduced. During boiling, THH may form from harmine and harmaline via reduction [Ref 31]. Heat processing does not meaningfully decarboxylate these alkaloids (unlike THCA→THC in cannabis), but extended reduction concentrates all alkaloids proportionally.

- **Pharmahuasca:** Synthetic analog using oral capsules of pure DMT + harmine. Ott (1999) [ref in search] confirmed full oral psychoactivity via self-experiments.
- **Anahuasca:** Uses different botanical sources (e.g., *Mimosa hostilis* for DMT, *Peganum harmala* for beta-carbolines) with similar pharmacological profile.

### Minor Alkaloids

*B. caapi* contains additional minor beta-carbolines including harmine-N-oxide, harmane, and others in trace quantities. These have limited published evidence for significant pharmacological contribution at concentrations present in typical brews. Not over-expanded here per research directives.

---

## History & Ethnobotany

### First Scientific Description

Richard Spruce, English botanist, first formally described *Banisteriopsis caapi* during his 1849–1864 Amazonian expedition, publishing as *Banisteria caapi* Spruce ex Griseb. (1858). The accepted binomial was formalized by C.V.Morton in 1931 [Ref 21]. Spruce documented indigenous use of the vine in the Rio Negro region of Brazil and among the Tukano people.

### Traditional / Indigenous Use

Ayahuasca has been used for centuries — likely millennia — across Northwestern Amazonian indigenous cultures spanning present-day Brazil, Peru, Colombia, Ecuador, Bolivia, and Venezuela [Refs 1, 27, 32]. Key traditional contexts:

- **Healing ceremonies:** Used to diagnose and treat illnesses, with the healer (curandero or ayahuascero/vegitalista) entering an altered state to access information about the patient's condition
- **Divination and guidance:** Consultation for spiritual, social, and practical matters
- **Initiation and rites of passage:** Particularly among young men in some Amazonian traditions
- **Purging (la purga):** The emetic and purging effects of ayahuasca are culturally integral, not incidental — regarded as physical and spiritual cleansing [Ref 27]. Indigenous ontologies understand purging as removal of spiritual pathogens.
- **Regional names and traditions:** Ayahuasca/Natem (Shuar, Ecuador); Yagé/Yajé (Tukano/Desana, Colombia); Hoasca/Vegetal (syncretic Brazilian churches); Caapi (various Brazilian groups); Cipó (Portuguese, used in Santo Daime)

McKenna et al. (1984) [Ref 10] identified the botanical constituents and confirmed the MAOI mechanism that had long been proposed by ethnobotanists. Earlier ethnobotanical work by Richard Evans Schultes (Harvard) from the 1940s–1960s documented uses across Colombia and Peruvian Amazon in foundational monographs.

**Traditional-use evidence note:** This historical use section relies substantially on ethnographic and ethnobotanical accounts. Published primary literature on traditional use pre-1980 is largely in anthropological/ethnographic format. **Flagged for human review where these are the primary evidence source.**

### Western Discovery and Research Timeline

- 1851: Spruce first Western botanical description
- 1931: C.V.Morton formalizes *Banisteriopsis caapi* binomial
- 1940s–1960s: Schultes extensive ethnobotanical fieldwork; first alkaloid isolation attempts
- 1958–1960s: Harmine, harmaline, and DMT isolated from *B. caapi* and admixture plants; chemical identity established
- 1984: McKenna et al. [Ref 10] demonstrate MAOI mechanism quantitatively; confirm synergy model is additive not synergistic
- 1993–2000: Hoasca Project (Callaway, Grob et al.) — first systematic human pharmacological and psychological study of ayahuasca in UDV members in Brazil
- 1999–2003: Riba, Barbanoj and colleagues in Barcelona conduct first European double-blind controlled clinical studies [Refs 11, 17, 36]
- 2006: US Supreme Court rules in *Gonzales v. O Centro Espírita Beneficente União do Vegetal* — first legal recognition of ayahuasca religious use in USA
- 2008: Peru designates ayahuasca ceremonial use as national cultural heritage
- 2015: First neuroimaging fMRI study (Palhano-Fontes et al.) [Ref 9]
- 2018: First RCT in treatment-resistant depression (Palhano-Fontes et al.) [Ref 7]
- 2020–2026: Rapid expansion of registered clinical trials; PBPK modeling; novel delivery systems [Refs 20, 26, 29, 30, 44, 45]

### Regulatory Timeline

- 1987: Brazil (CONAD) first formally regulates ayahuasca; religious/ceremonial use authorized — first national regulatory framework in the world
- 2006: US Supreme Court RFRA exemption (UDV); Santo Daime received similar protection subsequently
- 2008: Peru cultural heritage declaration
- 2019: Netherlands Supreme Court: ayahuasca falls under Opium Act (DMT content)
- 2022: Colorado (USA) decriminalizes natural psychedelics including ayahuasca (Proposition 122, November 2022)

---

## Neuroscience & Mechanism

### Primary Receptor Targets

**DMT (primary psychedelic constituent):**
- 5-HT₂A receptor: Partial agonist — principal mediator of psychedelic effects confirmed by ketanserin blockade in humans [Ref 17]. Activation causes EEG alpha-band power decrease in parietal/occipital cortex correlating with visual imagery.
- 5-HT₁A and 5-HT₂C: Partial agonist activity contributes to overall serotonergic profile [Refs 1, 2]
- Sigma-1 receptor (Sig-1R): Endogenous DMT ligand discovered; activates Sig-1R at mitochondria-associated membranes; roles in neuroprotection, cellular bioenergetics, immunoregulation, and anti-inflammatory signaling [Refs 32, 40]
- SERT: Substrate behavior (not blocker); Ki ~4.00 µM; allows intraneuronal accumulation for Sig-1R activation [Ref 41]
- VMAT2: Substrate behavior; Ki ~93 µM [Ref 41]
- TAAR1 (trace amine-associated receptor 1): Agonist activity documented [Ref 13]

**Beta-Carbolines:**
- Harmine, harmaline, THH: Reversible, competitive MAO-A inhibitors; prevent first-pass oxidative deamination of DMT by intestinal and hepatic MAO-A
- Without MAO-A inhibition: oral DMT produces no psychotropic effects (97% converted to indole-3-acetic acid/IAA) [Ref 16]
- Harmine additionally: DYRK1A kinase inhibitor; dopamine transporter inhibitor; imidazoline receptor ligand [Ref 6]
- THH additionally: Weak SERT inhibitor (serotonin reuptake inhibition) — may contribute anxiolytic/antidepressant component [Refs 4, 13]

### CNS Mechanism Summary

Harmine/harmaline inhibit intestinal and hepatic MAO-A, allowing orally-consumed DMT to reach systemic circulation intact. DMT crosses the blood-brain barrier and activates cortical 5-HT₂A receptors (primarily layer V pyramidal neurons). This drives decreased default mode network (DMN) activity — particularly posterior cingulate cortex (PCC)/precuneus and medial prefrontal cortex (mPFC) — and increased frontal and paralimbic activation [Refs 9, 36]. The net effect is disrupted hierarchical predictive processing (REBUS model), enabling enhanced bottom-up sensory information flow and the loosening of entrenched cognitive patterns — proposed to underlie both psychedelic phenomenology and therapeutic effects [cross-reference Carhart-Harris REBUS; not formally verified via tool in this run].

Sigma-1 receptor activation by DMT contributes additional neuroprotective, anti-inflammatory, and plasticity-promoting effects beyond serotonergic psychedelia [Ref 40]. Neuroplasticity (BDNF upregulation, dendritic remodeling) occurs after single and repeated exposure [Ref 37].

### Pharmacokinetics by Preparation Route

**Oral decoction (traditional/research-standard):**
- Onset: 20–60 min
- Peak effects: 1.5–2.5 h
- Duration: 4–8 h total (typically 4–6 h)
- DMT Cmax: 12.14 ng/mL at 0.6 mg DMT/kg; 17.44 ng/mL at 0.85 mg DMT/kg (Riba 2003 [Ref 11])
- DMT Tmax: ~1.5 h (Riba 2003 [Ref 11])
- Subject subjective peak: 1.5–2 h post-ingestion
- Diastolic BP increase: ~9 mmHg at 0.85 mg/kg dose [Ref 11]

**Buccal/transmucosal (research formulation):**
- DMT Cmax: 33 ng/mL; harmine Cmax: 49 ng/mL (Egger 2025 [Ref 26])
- Duration: 4–5 h
- Harmine markedly enhanced DMT bioavailability and prolonged absorption [Refs 26, 44]

**Smoked/inhaled (DMT alone — pharmahuasca analog):**
- Onset: seconds; peak: 5–20 min; duration: 15–30 min
- Fully psychoactive; IAA production drops to 63%; DMT-N-oxide and unmetabolized DMT rise [Ref 16]
- Harmine/beta-carbolines not required for smoked DMT activity

### CYP Enzyme Involvement

- DMT: Primarily metabolized by MAO-A (when available); also CYP2D6 and to lesser extent CYP3A4
- Harmine/harmaline: CYP2D6 and CYP1A2 substrates
- Key interaction risk: Fluoxetine and paroxetine (strong CYP2D6 inhibitors) predicted to significantly increase DMT and harmine plasma exposure when co-administered [Ref 29]
- THH: Not well-characterized at CYP level; minor contribution to beta-carboline pharmacology

### Blood-Brain Barrier

DMT readily crosses the BBB; endogenous DMT has been detected in human brain (consistent with INMT enzyme presence in CNS). The three-step active uptake mechanism proposed by Frecska et al. supports CNS accumulation from peripheral sources [Ref 40]. Peripheral (autonomic, neuroendocrine, immunological) effects also documented — prolactin elevation, cortisol elevation, CD4/CD3 decrease, NK cell increase [Ref 15].

---

## Effects & Dose by Preparation

### Traditional Aqueous Decoction (Primary Preparation)

**Dose:** Highly variable due to non-standardized preparation; typical ceremonial volume 100–200 mL per serving. Published clinical research doses: **0.6–1.0 mg DMT/kg body weight** [Refs 11, 15, 17] equivalent to roughly 42–70 mg DMT in a 70 kg adult.

| Parameter | Value | Source |
|-----------|-------|--------|
| Threshold | Not published for traditional brew as discrete tier | — |
| Common dose (research) | 0.6–0.85 mg DMT/kg | [Ref 11] |
| High dose (research) | 1.0 mg DMT/kg | [Ref 15] |
| Onset | 20–60 min | [Refs 1, 11] |
| Peak | 1.5–2.5 h | [Refs 11, 34] |
| Duration | 4–8 h | [Refs 1, 11, 26] |

**⚠️ FLAG: Dose tiers (threshold, common, heavy) as typically presented in the brief format are NOT available for the traditional brew from published primary sources. Ceremonial doses are highly variable and not standardized. The generation agent should present dose as a range from published research rather than fixed tiers.**

**Onset variation:** Ceremonial users often re-dose during ceremonies; peak DMT serum concentration does not reliably correlate with volume consumed — individual absorption/metabolism variation is large [Ref 34].

**Subjective effects profile (from controlled studies):**
- Complex visual hallucinations: geometric patterns, complex imagery, entity encounters, visionary narratives [Refs 9, 17, 34]
- Ego dissolution and oceanic boundlessness positively correlated with DMT Cmax [Ref 34]
- Enhanced introspection and emotional processing
- Cathartic emotional release; memory replays and personal insight
- Nausea and vomiting (common, especially within first 60 min) — culturally framed as "la purga" (the purge); integral to traditional use [Ref 27]
- Tachycardia, mild hypertension, pupillary dilation [Refs 11, 15]
- Default mode network suppression correlates with altered state intensity [Ref 9]
- Visual effects linked to 5-HT₂A activation in occipital/parietal cortex [Ref 17]

**Dose-response:** Ramaekers et al. (2023) [Ref 34] confirmed in naturalistic Santo Daime users that peak DMT serum concentration (not dose volume) drives primary phenomenological characteristics. This suggests individual variability in absorption/metabolism substantially moderates effects.

### Pharmahuasca (Standardized Research Analog)

Oral capsules containing pure DMT + harmine/harmaline. Ott (1999) confirmed psychoactivity and characterized the human pharmacology via self-experiment in multiple volunteers. Perkins et al. (2025) [Ref 25] used botanically-derived encapsulated DMT + harmala alkaloids in a Phase 1 study:
- Strong positive correlation between total dose and Mystical Experience Questionnaire (MEQ) scores
- Reliable acute subjective experiences exceeding scores in most naturalistic studies
- Onset ~30–60 min; duration ~4–5 h

### Effect Modifiers

- Chemotype/cultivar: B. caapi alkaloid content varies 27-fold in harmine across published samples [Refs 31, 42]; P. viridis DMT content varies from 0 to 17.65 mg/g
- Tolerance: Chronic ritual users may show neuroadaptive compensatory effects — Ramaekers 2023 [Ref 34] notes possible tolerance-like mitigation of mental imagery effects in long-term users; acute within-session psychological tolerance documented for intravenous DMT [referenced in Egger 2024]
- Setting (set and setting): Strongly influences subjective character of experience; ceremonial integration context associated with beneficial long-term outcomes in observational studies [Refs 24]
- Co-administration: Any concurrent serotonergic or dopaminergic drug substantially modifies effects and safety profile

---

## Safety & Toxicity

### Toxicological Data

- **LD50:** No specific published LD50 value in mg/kg for ayahuasca as a preparation was found in the peer-reviewed literature. **FLAGGED: The seed data claim that "LD50 is around 50 times a regular dose" cannot be verified against a primary published source.** The closest approximation comes from da Motta et al. (2018) [Ref 33]: rats dosed daily at 4× and 8× human equivalent doses over gestation days 6–20 experienced 44% and 52% mortality respectively, suggesting a therapeutic ratio consistent with the claim but not providing a formal LD50. Animal model doses were not acute single-dose LD50 protocols.
- **Cardiovascular:** Moderate sympathomimetic effects — diastolic BP increased ~9 mmHg at 0.85 mg/kg; tachycardia documented; prolactin and cortisol significantly elevated [Refs 11, 15]. Not comparable to amphetamine-level cardiovascular stimulation.
- **Neuroendocrine:** Significant prolactin increase (Dos Santos 2011 [Ref 15]); significant cortisol increase; time-dependent lymphocyte modulation (CD4/CD3 decrease, NK cell increase — normalized within 24 h).

### Adverse Events

- **Common acute adverse effects:** Nausea and vomiting (very common in traditional and research settings), diarrhea, headache, dizziness, tachycardia, anxiety, transient confusion
- **White et al. (2024) systematic review** [Ref 3] of 78 articles: Ayahuasca is generally safe; serious adverse human events are rarely reported in healthy populations in controlled settings; animal models at higher doses show potential toxicity; harmaline showed the most preclinical toxicity concerns
- **Psychological adverse effects:** Acute anxiety, fear, paranoia, confusion, overwhelm; persistent psychiatric complications reported in a subset of naturalistic users from retreat settings [Ref 24]. Psychosis precipitation possible in individuals with pre-existing vulnerability.
- **Case reports:** No specific fatal case reports attributable solely to ayahuasca were retrieved in this research run. However, MAOI + serotonergic drug combinations can produce life-threatening serotonin syndrome. **FLAGGED: Specific fatality case reports not identified via API search; the generation agent should note absence of documented fatalities from ayahuasca alone in controlled settings, while noting risk from MAOI interactions.**

### Developmental and Reproductive Toxicity

Da Motta et al. (2018) [Ref 33] — rat study, oral dosing gestation days 6–20:
- 4× and 8× human doses: significant mortality (44–52%); kidney injury
- 2× dose: neuronal loss in hippocampal CA1 region
- 8× dose: neuronal loss in hippocampus and raphe nuclei; delayed intrauterine growth; fetal anomalies; embryo deaths
- **Conclusion:** Ayahuasca is developmentally toxic in rats; daily use during pregnancy poses fetal risk. Formal extrapolation to humans is limited but this is a clear contraindication signal.
- **Traditional use note:** Indigenous accounts document some ceremonial use during pregnancy, but these are traditional-use reports without controlled evidence. **Flagged for human review.**

### Herb-Drug Interactions

| Interaction | Mechanism | Evidence Level | Risk |
|-------------|-----------|----------------|------|
| SSRIs (fluoxetine, paroxetine) | Pharmacokinetic (CYP2D6 inhibition) + pharmacodynamic (serotonin syndrome) | PBPK modeling [Ref 29] + pharmacodynamic mechanism | High |
| SNRIs (venlafaxine, duloxetine) | Pharmacodynamic serotonergic potentiation; also CYP2D6 interaction | Mechanistic reasoning | High |
| MAOIs (phenelzine, tranylcypromine, moclobemide) | Additive MAO-A inhibition; prolonged/intensified experience; serotonin syndrome risk | Pharmacodynamic mechanism | High |
| Tramadol | Serotonergic + CYP2D6 interaction; opioid component | Mechanistic reasoning | High |
| Lithium | Seizure risk; mechanism unclear | Case reports (not formally retrieved) | High — **FLAGGED: specific case reports not verified via API search** |
| Stimulants (amphetamines, cocaine) | Additive sympathomimetic + serotonergic | Pharmacodynamic mechanism | Moderate-high |
| Antipsychotics | Pharmacodynamic antagonism at 5-HT₂A; may blunt ayahuasca effects; QTc risk | Mechanistic reasoning | Moderate |
| Cardiac medications (antiarrhythmics, antihypertensives) | Additive cardiovascular effects; sympathomimetic interaction | Mechanistic reasoning | Moderate |

**Note on SSRI interaction:** The beta-carbolines are *reversible* MAO-A inhibitors (unlike phenelzine/tranylcypromine which are irreversible). Duration of MAOI activity from harmine/harmaline is shorter than irreversible MAOIs, but co-administration with serotonergic drugs within the session window remains high risk [Refs 4, 29].

### Tolerance and Dependence

- **Tolerance:** No development of behavioral tolerance across sessions in regular ritual users documented in published observational data [Refs 1, 12]. Acute within-session psychological tolerance to DMT observed in extended intravenous DMT administration study. Seed data characterizing preparation as "not habit-forming" is confirmed by published evidence.
- **Dependence:** No physical dependence; no characteristic withdrawal syndrome documented [Refs 5, 12]. Anti-addictive potential: 4 of 5 human observational studies showed reductions in substance dependence symptoms [Ref 5].
- **Long-term cognitive effects:** Fonseca et al. (2025) [Ref 28] cross-sectional study (n=48): no cognitive decline in long-term (>20 year) religious users; experienced users showed *higher* working memory scores vs beginners. Bouso et al. personality study (2026): chronic ayahuasca users distinguished by higher self-transcendence, lower harm avoidance, and lower persistence vs controls — not by cognitive impairment.

### Contaminant and Adulterant Risk

- **Alkaloid variability:** No standardized quality control for ceremonial preparations; inter-batch DMT variation is substantial [Refs 18, 31, 43]
- **Undisclosed admixture plants:** Ceremonial preparations may include additional botanicals (tobacco, *Brugmansia*, *Datura* species containing tropane alkaloids) without disclosure — risk of anticholinergic toxidrome with Brugmansia/Datura
- **Commercially sold brews:** Potential for non-botanical adulterants; potency may be misrepresented
- **Mold and contamination:** Aqueous decoctions stored improperly can support microbial growth; stability at room temperature is approximately 80 days for alkaloid content [Ref 31] but microbiological stability is not addressed in published literature

### Contraindications (Summary)

1. Severe cardiovascular disease (hypertension, arrhythmia, recent cardiac events)
2. Pregnancy (developmental toxicity data [Ref 33])
3. Personal or family history of psychosis, schizophrenia, schizotypal disorder
4. Acute bipolar disorder (mania risk not fully characterized)
5. Concurrent serotonergic medications (SSRIs, SNRIs, MAOIs, tramadol)
6. Severe hepatic impairment (harmine metabolism impaired)
7. Active psychotic disorders

---

## Harm Reduction

- **Set and setting:** Strong evidence-based predictor of adverse outcomes; ceremonial contexts with experienced facilitators associated with lower acute adverse event rates [Ref 24]
- **Medical screening:** Clinical trial protocols systematically exclude cardiac and psychiatric contraindications; retreat settings vary widely in screening rigor [Refs 20]
- **Medication washout:** Minimum washout of 2 weeks from SSRIs/SNRIs (longer for fluoxetine due to active metabolite norfluoxetine; 5 weeks recommended) before ayahuasca; 24 hours minimum abstinence from stimulants
- **Integration:** Observational data supports post-session psychotherapeutic integration for optimal outcomes and minimizing adverse effects [Ref 24]
- **Dose moderation:** Given inter-batch variability, conservative initial dosing (small volume; allow 60–90 min before re-dosing) recommended in community harm reduction frameworks
- **Test kits:** Standard Ehrlich reagent reacts with indole alkaloids including DMT (purple color); confirms presence but does not quantify or detect adulterants that are not indole-containing. Beta-carbolines (harmine etc.) will also react with Ehrlich.
- **ICEERS:** International Center for Ethnobotanical Education, Research and Service provides published harm reduction guidance specific to ayahuasca ceremonies (web-retrieved, not API-verified in this run)
- **Emergency guidance:** Acute serotonergic crisis (serotonin syndrome) requires immediate medical attention; treatment includes cyproheptadine (5-HT₂A antagonist) and supportive care; do NOT administer further serotonergic agents.

---

## Legal Status

### International Treaty Framework

- **UN 1971 Convention on Psychotropic Substances:** DMT is Schedule I (most restrictive). However, the 1971 Convention applies to pure chemical substances, not plants containing them. *Banisteriopsis caapi* and *Psychotria viridis* are **not** scheduled under the 1961, 1971, or 1988 UN drug control conventions. This creates a legal ambiguity exploited by religious organizations and in jurisdictions that have not domestically scheduled the plants [Ref 22].

### United States

- **Federal:** DMT is Schedule I of the Controlled Substances Act (CSA); manufacturing, distributing, or possessing ayahuasca is a federal felony.
- **Religious exemptions:** Two organizations hold federal RFRA exemptions — União do Vegetal (UDV; upheld by Supreme Court 2006, *Gonzales v. O Centro*) and Santo Daime.
- **State decriminalization:** Colorado Proposition 122 (November 2022) decriminalized natural psychedelics including ayahuasca. Several other municipalities (Oakland CA, Santa Cruz CA, Denver CO) have deprioritization resolutions.
- **Confidence level: High** (well-documented)

### Brazil

- CONAD (National Council on Drug Policy) regulations since 1987 authorize ceremonial use; re-affirmed and expanded in 2010. Religious/therapeutic ceremonial use is explicitly protected. Commercial non-ritualistic use and export prohibited.
- **Confidence level: High**

### Peru

- Traditional and ceremonial ayahuasca use legally recognized; National Institute of Culture declared ceremonial use a cultural heritage of indigenous communities (2008). No specific criminalization of the plants themselves.
- **Confidence level: High**

### Netherlands

- Dutch Supreme Court 2019: ayahuasca is prohibited under Opium Act due to DMT content; prior lower-court decisions allowing Santo Daime religious use were reversed. Possession, import, and distribution prohibited.
- **Confidence level: High** (Supreme Court ruling well documented)

### United Kingdom

- Class A drug under the Misuse of Drugs Act 1971 due to DMT content. No religious exemption in UK law. Possession carries up to 7 years imprisonment; supply up to life imprisonment.
- **Confidence level: High**

### Canada

- DMT is Schedule III under the Controlled Drugs and Substances Act. Religious exemptions for UDV and Santo Daime exist.
- **Confidence level: Moderate** (exemption details may require verification with Health Canada)

### Australia

- DMT is a Schedule 9 (prohibited substance) under the Poisons Standard. No religious exemptions known. No known prosecutions for personal ceremonial use reported as of research date.
- **Confidence level: Moderate**

### Germany

- DMT is illegal under the Narcotics Act (Betäubungsmittelgesetz/BtMG). Ayahuasca preparation is illegal; plants alone are not explicitly listed but preparation is prohibited. Religious organizations face legal challenges.
- **Confidence level: Moderate**

### Colombia

- Historically tolerant of traditional indigenous use; ayahuasca use by indigenous populations in ceremonial contexts is legally protected under constitutional rights of indigenous peoples. Commercial/tourist use is in legal grey area.
- **Confidence level: Low** — **FLAGGED for human review; specific legislation not confirmed via primary source retrieval in this run.**

---

## Clinical Trials

**Active/recently completed trials from ClinicalTrials.gov search:**

| NCT ID | Title | Phase | Status | Sponsor | Relevance |
|--------|-------|-------|--------|---------|-----------|
| NCT07212946 | Ayahuasca and esketamine for major depression | Phase 2 | Completed | University of Sao Paulo | Head-to-head comparison |
| NCT07317206 | Ayahuasca, esketamine and PTSD | Phase 2 | Recruiting | University of Sao Paulo | PTSD indication |
| NCT07317232 | Ayahuasca, esketamine and premenstrual symptoms | NA | Recruiting | University of Sao Paulo | Novel indication |
| NCT06150859 | Ayahuasca-assisted psychotherapy for grief | Phase 2 | Unknown | Beckley Med Foundation | Grief/bereavement indication |
| NCT06252506 | Molecular imaging of harmine/DMT | Phase 1 | Completed | Univ. Hospital Bern | Mechanistic/PK imaging |

**Landscape summary (Stojanovic et al. 2026 [Ref 20]):** 26 registered trials identified as of review; most Phase I, majority completed; expanded rapidly after 2020–2021; primarily DMT-only trials sponsored by academic/hospital institutions; eligibility conservative (healthy psychiatric/medically stable adults, extensive cardiovascular exclusions); small set of depression-focused trials with preliminary evidence.

**Meta-analytic evidence:**
- Yao et al. (2024) [Ref 38]: Ayahuasca/DMT for mood disorders — Hedges' g = −1.34 [95% CI −1.86, −0.82]; strong effect size but based on limited trials
- Hojlund et al. (2025) [Ref 39]: Psilocybin/ayahuasca/LSD combined for MDD — SMD = −0.62 [95% CI −0.97, −0.28]; GRADE evidence certainty very low
- Palhano-Fontes et al. (2018) [Ref 7]: First RCT in TRD — Cohen's d = 1.49 at day 7; response rate 64% ayahuasca vs 27% placebo (n=29)

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief. This section is accordingly blank.

---

## Gaps & Flags

### Safety-Critical Gaps

1. **LD50 (formal value):** ⚠️ The seed data states "LD50 is around 50 times a regular dose." No peer-reviewed published LD50 (mg/kg, acute, single dose) for ayahuasca as a preparation was identified in this research run. The da Motta 2018 [Ref 33] rat study provides developmental toxicity data (not acute LD50). The generation agent should present this approximate claim with appropriate uncertainty and not imply it is a formally established value.

2. **Lithium interaction:** ⚠️ Case reports of seizures with ayahuasca + lithium are referenced in harm reduction literature and clinical practice guidelines, but specific peer-reviewed case reports were not retrieved via PubMed/OpenAlex searches in this run. The generation agent should note this as a high-risk interaction with mechanistic plausibility but acknowledge limited formal case report evidence retrieved.

3. **Fatal adverse events:** No published case reports of death attributable solely to ayahuasca consumed as traditional brew were retrieved in API searches. This is likely accurate for controlled settings; uncontrolled use with MAOI combinations poses life-threatening risks (serotonin syndrome). The generation agent should frame the safety profile accordingly.

4. **Serotonin syndrome case reports with ayahuasca:** Specific published case reports were not retrieved in this run. The SSRI interaction is well-characterized mechanistically [Ref 29] but formal case series documentation was not verified.

### Data Quality Gaps

5. **Dose tiers for traditional preparation:** No published primary source provides discrete threshold/common/heavy dose tiers for traditional aqueous ayahuasca brew in a format appropriate for the brief's dose template. Clinical research doses (0.6–1.0 mg DMT/kg) are the best-characterized reference. The generation agent should present these research doses as reference points, with a note that traditional ceremonial doses vary widely and are not standardized.

6. **Duration data by preparation route:** Duration for traditional brew (4–8 h) is derived from multiple clinical studies but not from a single definitive source. The range is well-supported across multiple papers.

7. **Psychotria viridis POWO taxonomy:** Not retrieved via POWO API in this run. P. viridis botanical identity is well-established from multiple primary sources (McKenna 1984 [Ref 10], Fonseca 2025 [Ref 28]) but the formal POWO entry was not accessed. **Flagged for human review.**

8. **Diplopterys cabrerana alkaloid profile vs P. viridis:** No published comparative pharmacokinetic data on how these admixture plant substitutions alter brew potency or DMT bioavailability in human subjects. Noted as data absent.

9. **Colombia legal status:** Confidence level low. The generation agent should note uncertainty and flag for editorial verification.

10. **Drug test detection:** Standard 5-panel and 10-panel urine immunoassay screens do NOT test for DMT or beta-carbolines. Specialized GC-MS or LC-MS/MS methods required for detection. Detection window in saliva/serum approximately 24 h (Lanaro 2021 [Ref 14]). The generation agent should note that standard drug screens will not detect ayahuasca use.

11. **Admixture plant variation on pharmacology:** The McKenna 1984 [Ref 10] study identified three main admixture plants (P. viridis, P. carthagenensis, D. cabrerana) but there are no published human pharmacokinetic comparison studies across these. The claim that different admixtures produce qualitatively different experiences is from ethnographic accounts only. **Traditional-use-only evidence for this claim — flagged for human review.**

12. **Contraindication in liver disease:** Presented as mechanistic reasoning (harmine is CYP2D6/hepatic substrate). No clinical case reports of hepatotoxicity with ayahuasca were retrieved. **Mechanistic basis only — not backed by clinical case reports.**

13. **Interaction severity ratings:** All herb-drug interaction severities above are based on mechanistic pharmacokinetic/pharmacodynamic reasoning, not clinical case reports, except for the SSRI/CYP interaction which has PBPK modeling support [Ref 29]. **Flagged per research directives.**

14. **Sections relying on traditional-use evidence only:**
    - Preparation methods (traditional steps, boiling procedures)
    - Additional admixture plant species pharmacological equivalence
    - Purging as therapeutic mechanism
    - Some ethnogeographic claims about specific tribes and their ceremonial uses
    All above are cited to ethnobotanical/ethnographic literature and should be labeled as traditional-use accounts in the generated article.